Want to see EOLS full AI Analyst Report?
EOLS Stock Chart & Stats
$5.98
$0.20(3.34%)
At close: 4:00 PM EDT
$5.98
$0.20(3.34%)
Day’s Range― - ―
52-Week Range$3.86 - $9.35
Previous Close$6.18
Volume650.24K
Average Volume (3M)756.56K
Market Cap
$397.10M
Enterprise Value$383.03
Total Cash (Recent Filing)$49.79M
Total Debt (Recent Filing)$164.90M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 05, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding65,854,750
10 Day Avg. Volume763,153
30 Day Avg. Volume756,558
Financial Highlights & Ratios
PEG Ratio6.73
Price to Book (P/B)-18.55
Price to Sales (P/S)1.44
P/FCF Ratio-8.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.50Price Target Upside142.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.09
Revenue Forecast (FY)$330.45M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth & High Gross MarginsSustained multi-year top-line expansion and durable ~65% gross margins indicate strong product economics and pricing power for Jeuveau. This supports long-term unit economics, higher contribution per treatment, and a structural ability to fund marketing and R&D as revenue scales.
Improving Adjusted EBITDA And Profitability GuidanceConsecutive positive adjusted EBITDA and management's reiterated expectation of full-year adjusted EBITDA profitability reflect durable operating-leverage gains and tighter cost control. If sustained, this reduces reliance on external financing and improves the firm's ability to reinvest in growth initiatives.
Portfolio Diversification Via Profhilo U.S. DistributionAdding Profhilo structurally broadens Evolus' injectable portfolio into skin-quality treatments and an underpenetrated U.S. segment. The transfer-price, no-upfront deal is capital-efficient, leverages existing commercial channels, and meaningfully expands addressable market and cross-sell options over time.
Bears Say
Levered Balance Sheet With Negative EquityNegative equity and elevated debt materially weaken financial flexibility and increase refinancing risk. This structural leverage limits the company's capacity to absorb shocks, raises financing costs, and constrains strategic options such as opportunistic M&A or larger investments without external funding.
Persistent Negative Operating And Free Cash FlowOngoing negative operating and free cash flow means Evolus must rely on external capital or debt to fund operations and launches. Over a multi‑month horizon this increases dilution or leverage risk, limits self-funding for product rollouts, and leaves the company vulnerable if capital markets tighten.
Product Concentration & Competitive PressureRevenue remains concentrated in Jeuveau while Evolisse contribution is small and fillers face incumbents and a flat market. New neurotoxin entrants and sampling dynamics could pressure share and require sustained investment to defend, making future growth dependent on successful launches and market penetration.
Evolus News
EOLS FAQ
What was Evolus, Inc.’s price range in the past 12 months?
Evolus, Inc. lowest stock price was $3.86 and its highest was $9.35 in the past 12 months.
What is Evolus, Inc.’s market cap?
Evolus, Inc.’s market cap is $397.10M.
When is Evolus, Inc.’s upcoming earnings report date?
Evolus, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 4 days.
How were Evolus, Inc.’s earnings last quarter?
Evolus, Inc. released its earnings results on May 04, 2026. The company reported -$0.046 earnings per share for the quarter, beating the consensus estimate of -$0.113 by $0.067.
Is Evolus, Inc. overvalued?
According to Wall Street analysts Evolus, Inc.’s price is currently Undervalued.
Does Evolus, Inc. pay dividends?
Evolus, Inc. does not currently pay dividends.
What is Evolus, Inc.’s EPS estimate?
Evolus, Inc.’s EPS estimate is -0.04.
How many shares outstanding does Evolus, Inc. have?
Evolus, Inc. has 65,854,750 shares outstanding.
What happened to Evolus, Inc.’s price movement after its last earnings report?
Evolus, Inc. reported an EPS of -$0.046 in its last earnings report, beating expectations of -$0.113. Following the earnings report the stock price went up 14.158%.
Which hedge fund is a major shareholder of Evolus, Inc.?
Currently, no hedge funds are holding shares in EOLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.50 (142.47% Upside)
$14.50 (142.47% Upside)
Blogger Sentiment
Bullish
EOLS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 11.1%
Last 30 Days ▼ 11.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.41%
Trailing 12-Months
Company Description
Evolus, Inc.
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
EOLS Company Deck
EOLS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly constructive picture: revenue growth (Q1 +7%), healthy margins (adjusted gross margin 68%), expanding commercial footprint and loyalty (Rewards members +27% YoY), and a return to positive adjusted EBITDA ($0.6M) alongside reiterated full-year guidance and planned product launches (Esteem in Europe, Sculp FDA in Q4). Key risks include timing/seasonality comparatives, a newly announced 15% South Korea tariff on certain products, a still-small contribution from Evolisse amid a soft filler market, and continued competitive entrants. On balance, the operational improvements, profitability momentum, and clear pipeline/launch cadence outweigh the cited headwinds.View all EOLS earnings summariesEOLS Stock 12 Month Forecast
Average Price Target
$14.50
▲(142.47% Upside)
Technical Analysis
Emergent Biosolutions
―
Rockwell Med
―
Organogenesis Holdings
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Ownership Overview
3.13% Insiders
7.96% Mutual Funds
1.74% Other Institutional Investors
75.08% Public Companies and
Individual Investors